CALGB 49907 trial: Standard chemotherapy versus capecitabine for older women with early stage breast cancer | Dr Hyman Muss at Annual Meeting 2015

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Hyman Muss, MD, of the University of North Carolina, Chapel Hill, NC, provides an update on the CALGB/CTSU/Alliance 49907 trial, which compared capecitabine with standard chemotherapy in patients with breast cancer who were at least 65 years old.

European Medical Journal

Website: http://emjreviews.com/
Twitter: https://twitter.com/EMJReviews
Facebook: https://www.facebook.com/emjreviews